Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer

6Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 146 patients with docetaxel-naïve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai, China) in this retrospective cohort study. The efficacy endpoints were prostate-specific antigen response rate, prostate-specific antigen progression-free survival, clinical/radiographic progression-free survival, and overall survival in response to abiraterone plus prednisone. Significantly higher prostate-specific antigen response rate was found in docetaxel-naïve group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naïve group compared to docetaxel-resistant group, respectively. The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival. To sum up, our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naïve and docetaxel-resistant Chinese patients. Moreover, higher PSA response rate and longer overall survival were observed in the docetaxel-naïve group, which suggested that abiraterone was more effective for docetaxel- naïve patients than for docetaxel failures.

References Powered by Scopus

Cancer statistics, 2016

23657Citations
N/AReaders
Get full text

Cancer statistics in China, 2015

16926Citations
N/AReaders
Get full text

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

4743Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: A systematic review

24Citations
N/AReaders
Get full text

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?

12Citations
N/AReaders
Get full text

Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lin, G. W., Li, G. X., Dai, B., Ye, D. W., Kong, Y. Y., Wang, Y., & Shen, Y. J. (2019). Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 21(2), 131–136. https://doi.org/10.4103/aja.aja_85_18

Readers over time

‘18‘19‘20‘21‘22‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

50%

Researcher 2

33%

Lecturer / Post doc 1

17%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 2

33%

Medicine and Dentistry 2

33%

Computer Science 1

17%

Engineering 1

17%

Save time finding and organizing research with Mendeley

Sign up for free
0